Physician profile
Robert E Lahasky
NPI 1922086339
$12,771.03
in general payments reported to CMS, 2019-2025
39 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,351 · 2020: $1,839 · 2021: $2,115 · 2022: $2,208 · 2023: $2,399 · 2024: $1,105 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,258.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,989.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,523.26 | 2019-2024 | |
| Novo Nordisk INC | $926.27 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $908.88 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $846.78 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Allergan, INC. | $828.44 | 2019-2021 | |
| Amgen INC. | $718.83 | 2019-2025 | Repatha, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $677.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $666.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $388.04 | 2019-2025 | Trintellix |
| Corium, LLC | $352.42 | 2022-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $331.55 | 2021-2025 | |
| Astellas Pharma US INC | $300.73 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $240.01 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $202.83 | 2019-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $181.16 | 2019-2023 | Belsomra, Steglatro |
| Idorsia Pharmaceuticals US INC | $177.59 | 2022-2023 | Quviviq |
| Dexcom, INC. | $148.59 | 2021-2024 | Dexcom G6 Transmitter |
| Teleflex LLC | $131.99 | 2023 | Urolift |
| Abbott Laboratories | $121.70 | 2022-2024 | Freestyle Libre 3 |
| Verona Pharma, INC. | $121.69 | 2025 | Ohtuvayre |
| Eisai INC. | $103.82 | 2020-2021 | |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| Coloplast Corp | $98.98 | 2023 | Titan |
| Phathom Pharmaceuticals, INC. | $96.00 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $84.35 | 2019-2022 | |
| Biogen, INC. | $74.87 | 2020-2024 | Skyclarys, Skyclarys |
| Novartis Pharmaceuticals Corporation | $70.45 | 2019-2022 | |
| Sanofi Pasteur INC. | $65.88 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.84 | 2019-2020 | |
| Axsome Therapeutics, INC. | $52.12 | 2022-2025 | Auvelity |
| Exact Sciences Corporation | $36.99 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $26.85 | 2020-2022 | |
| Almatica Pharma LLC | $26.83 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $25.02 | 2023 | Prehevbrio |
| Shire North American Group INC | $24.75 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.90 | 2021 | |
| Neos Therapeutics, Lp | $15.73 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lahasky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.